- Home
- IIIV vs EYPT Comparison
IIIV vs EYPT Comparison
Compare IIIV & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IIIV | EYPT |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.0M | 419.9M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IIIV | EYPT |
|---|---|---|
| Price | $14.73 | $3.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $33.20 | $31.80 |
| AVG Volume (30 Days) | 445.2K | ★ 4.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.07 | $3,115.57 |
| P/E Ratio | $61.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $3.95 |
| 52 Week High | $33.97 | $19.11 |
Technical Indicators
Market Signals| Indicator | IIIV | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 28.76 |
| Support Level | $15.59 | $3.95 |
| Resistance Level | $17.12 | $18.99 |
| Average True Range (ATR) | 0.66 | 0.29 |
| MACD | 0.05 | 0.19 |
| Stochastic Oscillator | 28.29 | 12.76 |
Price Performance
Historical ComparisonAbout IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.